EP3849534
Samsetning af dasatíníb og adagrasíb til notkunar við meðhöndlun á ekki-smáfrumu lungnakrabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
9.9.2019EP published:
5.3.2025EP application number:
19858883.2
EP translation filed:
7.5.2025Grant published:
15.6.2025EPO information:
European Patent Register
Max expiry date:
8.9.2039Expiry date:
8.9.2026Next due date:
30.9.2026
Title in English:
COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCERLanguage of the patent:
English
Timeline
Today
9.9.2019EP application
5.3.2025EP Publication
7.5.2025Translation submitted
15.6.2025Registration published
8.9.2026Expires
Owner
Name:
Mirati Therapeutics, Inc.Address:
Route 206 and Province Line Road, Princeton, New Jersey 08543, US
Inventor
Name:
ENGSTROM, Lars, DanielAddress:
Carlsbad, CA 92009, US
Name:
ARANDA, Ruth, WeiAddress:
San Diego, CA 92108, US
Name:
OLSON, PeterAddress:
San Diego, CA 92122, US
Name:
CHRISTENSEN, James, GailAddress:
San Diego, CA 92130, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862729169 PDate:
10.9.2018Country:
US
Classification
Categories:
A61K 31/5025, A61K 31/506, A61K 31/517, A61K 31/519, A61K 31/5377, A61K 31/541, A61K 31/553, A61K 45/06, A61P 35/00, A61P 35/02, A61K 9/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 9.9.2025
Expires: 8.9.2026
Payer: Árnason Faktor ehf.